To translate randomised controlled trial terminology accurately, a translator must preserve the design logic that separates random sequence generation, allocation concealment, blinding, comparison groups and analysis populations. These terms often appear together, but they are not interchangeable. A trial can use a genuinely random allocation sequence yet fail to conceal upcoming assignments. It can conceal allocation perfectly yet be impossible to blind participants after treatment begins. A target-language report that collapses all of these ideas into one vague phrase such as “double-randomised and blind” can change how readers judge the evidence.
This guide explains how to translate randomised controlled trials, randomization, allocation concealment, blinding, masking, placebo controls, control groups, intention-to-treat analysis, per-protocol analysis and trial flow. It is intended for educational texts, research summaries, clinical-trial reports, evidence reviews and multilingual science communication. All examples are fictional. The article explains language and study-design meaning; it does not provide medical advice, evaluate a real treatment or replace the protocol and statistical analysis plan of an actual trial.
The core translation method is to map every term to the stage of the trial it controls. Sequence generation concerns how assignments are created. Allocation concealment concerns whether the next assignment can be known before enrolment is irrevocably entered. Blinding concerns who knows the assigned intervention after allocation. Placebo and active controls concern what groups receive. Analysis labels such as intention-to-treat concern which participants are analysed in which groups. Once these stages are separated, the target prose can be natural without turning one safeguard into another.
A fifty-second orientation
The Cochrane Handbook chapter on risk of bias in randomized trials distinguishes allocation-sequence generation from allocation-sequence concealment and from blinding. Allocation concealment prevents foreknowledge of upcoming assignments before allocation. Blinding, by contrast, is intended to reduce bias after assignment when knowledge of the intervention might influence behaviour, care or outcome assessment. These are separate safeguards and should remain separate in translation.
A compact working map is useful: generate the sequence → conceal the next assignment → enrol and allocate → deliver interventions → maintain or assess blinding where possible → measure outcomes → analyse according to the prespecified strategy. Every design term belongs somewhere on this path. If the translated term moves to another stage, the study description changes even when the sentence still sounds scientific.
1. Randomised does not simply mean mixed or varied
In a randomised controlled trial, participants are assigned to comparison groups using a random process. The purpose is not to make the study feel unpredictable in an everyday sense. Random allocation supports comparability by making treatment assignment independent of investigator preference under the design.
A target-language word meaning “haphazard,” “arbitrary” or “unsystematic” may therefore be misleading. Randomisation is systematic precisely because the method is specified, but the assignments are generated through a random mechanism. The translator should preserve both structure and unpredictability.
If the source names the method—computer-generated random numbers, random-number tables, stratified randomisation or another procedure—keep that method. Do not generalise a specific sequence-generation process into “participants were randomly chosen” unless the source is actually describing random sampling. Random assignment and random sampling are different operations.
2. Random sampling and random assignment answer different questions
Random sampling concerns how participants are selected from a broader population. Random assignment concerns how enrolled participants are placed into study groups. A trial can randomly assign volunteers who were not randomly sampled from the population. The causal and generalisability implications are therefore different.
A translation that turns “participants were randomly assigned” into “participants were randomly selected” changes the study design. The first supports internal comparison between intervention groups; the second would claim a sampling mechanism that may not exist.
Write the two questions in your review notes: “Who entered the study?” and “How were enrolled participants assigned to groups?” If the source answers only the second, do not invent an answer to the first. The distinction is foundational and should be protected before any stylistic rewriting begins.
3. Random sequence generation is the creation of assignments
Random sequence generation refers to how the allocation sequence itself is produced. In a two-group trial, the sequence might look like A, B, B, A, A, B and so on, generated under a specified random procedure. The scientific question is whether the method produces an unpredictable sequence under the design.
A report saying “a computer-generated randomisation list was created” should not be translated as “the computer decided treatment after the participant arrived” unless the system actually did real-time assignment. The list may have been generated in advance and then concealed. Sequence generation and implementation are separate steps.
Similarly, alternating assignment—A, B, A, B—is predictable and is not random sequence generation merely because investigators do not personally choose each group. If the source distinguishes quasi-random methods from genuine randomisation, preserve that distinction.
4. Allocation concealment protects the next assignment before enrolment
Allocation concealment prevents recruiters or participants from knowing the upcoming group assignment before the participant is irreversibly enrolled and allocated. The Cochrane Handbook emphasises that this is a vital part of protecting the randomisation process. If future assignments can be predicted or inspected, enrolment decisions may be influenced.
The translation trap is to treat allocation concealment as another word for blinding. It is not. Concealment occurs around assignment and protects against foreknowledge of the next allocation. Blinding concerns knowledge of treatment after allocation. One can be implemented even when the other is impossible.
A useful first-use explanation is “the upcoming assignment was hidden from those enrolling participants until allocation occurred.” This makes the timing visible. A target phrase that says merely “the treatment was kept secret” is too vague to establish which stage was protected.
5. Sealed envelopes are not automatically adequate concealment
Some trial reports use sequentially numbered, opaque, sealed envelopes as an allocation method. The design details matter. Envelopes that are translucent, unsealed, accessible out of order or opened before enrolment can fail to conceal future assignments.
A translator should therefore preserve qualifiers such as sequentially numbered, opaque and sealed rather than reducing the phrase to “envelope method.” Those adjectives describe safeguards. Removing them can make an adequately described method look weaker—or can make a poorly described method look stronger if the target adds safeguards not present in the source.
If the source is unclear, translate what is stated. Do not upgrade “sealed envelopes” to “securely concealed allocation” without evidence. Study-design translation is not a quality-improvement exercise. It must preserve the level of methodological information the authors actually provide.
6. Central randomisation separates recruitment from assignment information
A central randomisation service can help protect allocation by keeping the assignment mechanism separate from the recruiting site. The source may describe a web-based, telephone-based or pharmacy-controlled system. Translate the actual mechanism rather than replacing it with a generic “computer randomisation” label.
The important relationship is who can know the assignment and when. A system may use a computer for sequence generation but still reveal the entire list to recruiters, which would undermine concealment. Conversely, a central service can reveal only the current participant’s assignment after enrolment.
Do not infer security properties from the technology name alone. “Web-based” does not automatically mean concealed, audited or inaccessible. Preserve the source’s description of process and access, because those details are what support the methodological claim.
7. Blinding begins after allocation
Blinding, also called masking in some fields, concerns whether participants, care providers, investigators, outcome assessors or analysts know which intervention was assigned. The purpose can be to reduce changes in behaviour, care, measurement or interpretation caused by that knowledge.
A source may specify exactly who was blinded. Preserve that list. Saying “the trial was blinded” without identifying the parties can be less informative than the source. It may also be misleading when some roles were blinded and others were not.
The timing matters. A participant can be assigned to a group under perfectly concealed allocation and then immediately know which treatment they received. That trial may have adequate allocation concealment but no participant blinding. Translation should keep both facts rather than treating one as evidence of the other.
8. Masking and blinding can be synonyms, but conventions differ
Some journals and disciplines prefer masking rather than blinding. The two terms can refer to the same general methodological idea, but the source’s preferred terminology should be respected. A target technical community may also have an established conventional term.
Do not alternate between two target terms for stylistic variety if readers may think they describe different procedures. Methodological prose benefits from deliberate repetition. Once a term is defined, consistency is usually more important than elegance.
If the source uses both terms because it is discussing terminology itself, preserve the distinction and explanation. Do not silently harmonise them into one word when the author is explicitly comparing usage conventions.
9. “Single-blind” and “double-blind” can hide important ambiguity
Labels such as single-blind and double-blind are familiar but can be ambiguous because different reports may use them for different combinations of blinded parties. One trial may call itself double-blind because participants and clinicians are blinded; another may mean participants and outcome assessors.
When the source specifies who was blinded, translate those roles directly rather than relying only on the shorthand. “Participants and outcome assessors were blinded” is methodologically clearer than “double-blind” by itself.
If the source provides only the shorthand, do not invent the missing roles. Preserve the term and, if appropriate, note that the report does not specify the blinded parties. Translation should not manufacture methodological detail to make the article seem more complete.
10. Blinding may be impossible for some interventions
In some trials, participants or providers cannot realistically be blinded to the intervention. A surgical procedure compared with no surgery, a physical training programme or an educational intervention may reveal the assigned condition. Lack of blinding is therefore not automatically evidence that investigators were careless.
Translation should preserve any source discussion of feasibility and alternative safeguards. Outcome assessors may be blinded even when participants are not. Objective outcomes may be less susceptible to some forms of knowledge-related bias than subjective outcomes. The study’s risk-of-bias reasoning depends on the specific pathway.
A target summary that simply says “the trial was not properly blinded” can impose a negative judgement not made by the source. Translate the actual design and limitations rather than converting a descriptive statement into an evaluation.
11. Placebo control describes the comparator, not the randomisation method
A placebo is an inactive or comparison intervention designed to resemble aspects of the active intervention while lacking the specific active component under study. A placebo-controlled trial compares an intervention group with such a comparator under the protocol.
Placebo control does not itself prove that participants were randomly assigned, allocation was concealed or blinding was successful. These are separate design features. A placebo may facilitate blinding, but the report must establish how it was used.
Do not translate placebo as “fake treatment” in formal technical prose unless the intended audience and source justify that simplification. “Inactive comparison treatment” may be more precise for general readers, while specialist publications may retain the established term placebo.
12. Placebo and no-treatment controls are different comparators
A no-treatment control receives no corresponding intervention, while a placebo-control group receives a comparator designed to mimic some aspects of treatment experience. These designs can differ in expectations, contact, procedures and blinding possibilities.
Translation must not replace “no-treatment control” with placebo simply because both are control groups. The comparator defines what causal contrast the trial estimates. An active intervention versus placebo answers a different practical question from active intervention versus usual care or versus no intervention.
A table heading may use compact labels such as placebo, usual care, standard treatment or wait-list. Keep those distinctions. If the target audience needs explanation, define the comparator rather than collapsing all of them into “control.”
13. Active control means a real comparator intervention
An active-controlled trial compares the intervention of interest with another active intervention. The comparator might be an established treatment, another dose or another programme. The purpose and interpretation depend on the trial objective.
A target phrase such as “positive control” can be inappropriate if it has another technical meaning in the field. Preserve the established trial-design term used by the source and target discipline.
Also preserve whether the trial is designed for superiority, non-inferiority or equivalence. These objectives are not synonyms. A trial failing to show superiority does not automatically prove equivalence. Translating one objective into another can reverse the evidential claim.
14. Parallel-group and crossover designs organise exposure differently
In a parallel-group trial, participants remain in their assigned groups across the comparison period. In a crossover trial, participants may receive multiple interventions in sequence under a specified design. The same person can therefore contribute observations under more than one condition.
A translation that turns crossover into “participants changed groups” can be too informal and may suggest protocol deviation. In a planned crossover, switching conditions is part of the design. Terms such as period, sequence and washout may be important.
Keep the unit of randomisation visible. Some crossover trials randomise sequences rather than permanently assigning each participant to one intervention. The source design should determine the target explanation.
15. Cluster randomisation assigns groups rather than individuals
In a cluster-randomised trial, intact groups such as schools, clinics or communities may be randomised. Outcomes may still be measured on individuals, but the unit of allocation is the cluster. Translation must preserve that level.
A source saying “20 schools were randomised” should not become “students were randomly assigned” unless individual randomisation also occurred. The statistical analysis often accounts for correlation among individuals within the same cluster.
Terms such as cluster, site and centre can have overlapping everyday meanings but different design roles. Use the source definition. A hospital site is not necessarily the randomisation cluster, and a classroom is not automatically the analysis unit.
16. Stratified randomisation and blocking are design tools, not subgroup results
Stratified randomisation can help balance allocation within predefined strata, while blocking can help maintain group balance as enrolment proceeds. These procedures influence the allocation process. They are not the same as analysing treatment effects within subgroups after the trial.
A translation that turns “stratified by site and age group during randomisation” into “results were stratified by site and age” changes a design feature into an analysis description. Keep the timing and purpose of stratification explicit.
When block size is concealed or varied, preserve those details if the source reports them. Predictable fixed blocks can sometimes make future assignments easier to guess if recruiters know the pattern. The design terminology carries risk-of-bias information.
17. Intention-to-treat analysis follows randomised assignment
An intention-to-treat approach generally aims to analyse participants according to the groups to which they were randomised, regardless of later adherence or treatment changes, subject to the precise study definition and data availability. The concept preserves the comparison created by randomisation.
Do not translate intention-to-treat as “participants who intended to receive treatment.” The intention belongs to the analytic principle, not to participant motivation. This is a classic example where literal everyday meaning is misleading.
If the source says modified intention-to-treat, preserve the modification and its stated rules. Different studies use the term differently. A translator should not silently simplify modified ITT to ITT when exclusions or additional eligibility conditions are part of the analysis set.
18. Per-protocol analysis uses a different analysis population
Per-protocol analyses typically focus on participants who met defined protocol-adherence criteria. They can answer different questions from intention-to-treat analyses and may be affected by post-randomisation selection. The exact criteria should come from the source protocol.
A target phrase such as “correct participants only” is inappropriate. Protocol adherence is not moral correctness. Translate the defined eligibility for the analysis population rather than adding judgement.
When a report presents both ITT and per-protocol results, keep the analysis labels attached to the correct estimates. A table can become misleading if headings are translated correctly but shifted one column during formatting.
19. Attrition and missing outcomes belong to the trial flow
Participants may withdraw, become lost to follow-up or have missing outcome measurements. These events affect the analysis and potential bias. Translation should preserve the difference between withdrawal from treatment, withdrawal from follow-up and missing a particular measurement.
A participant who stops the assigned treatment may still provide outcome data. A target summary saying “dropped out of the study” can therefore be inaccurate if the source says only “discontinued intervention.” Trial flow terminology must remain precise.
Keep numbers consistent across enrolment diagrams and prose. If 200 are randomised, 190 complete follow-up and 185 are analysed, the target should explain where the differences arise according to the source. Do not repair arithmetic discrepancies silently; query them.
20. Outcome assessors and adjudicators may have different roles
An outcome assessor measures or determines study outcomes. An adjudication committee may review complex events using predefined criteria. These roles can be blinded independently of participants or treating clinicians.
Translating all such roles as “researcher” removes the methodological information. If the report says blinded outcome assessor, keep the assessor role and blinding status. If adjudicators review events without knowledge of treatment allocation, preserve that specific safeguard.
Do not assume the person collecting raw data is the same person who determines the final endpoint. Large trials can separate collection, coding, adjudication and statistical analysis. Translate the workflow the source actually describes.
21. Prespecified outcomes differ from post hoc analyses
A prespecified outcome or analysis is defined before examining the relevant results according to the study plan. A post hoc analysis is developed after data are available. The evidential status can differ because data-dependent choices may increase the risk of selective interpretation.
A translation that turns post hoc into “additional” may erase the timing. Additional analysis can be prespecified; post hoc specifically signals that it was not part of the original plan in that form.
Preserve words such as exploratory, confirmatory, primary, secondary and sensitivity when the source uses them. These labels organise claims. They are not decorative headings that can be freely exchanged for stylistic variety.
22. Primary and secondary outcomes carry hierarchy
A primary outcome is typically the main outcome on which the trial’s central evaluation is based. Secondary outcomes provide additional information. The protocol and statistical plan define their exact roles.
Do not translate secondary as less important in an everyday sense. A secondary outcome can be clinically important while occupying a different prespecified inferential position. The term indicates hierarchy in the study design, not human value.
When multiple primary outcomes exist, preserve whether they are co-primary, composite or separate. A target phrase like “main outcomes” may be too vague if the statistical decision rule depends on all co-primary endpoints being met.
23. A worked design example from recruitment to analysis
Consider a fictional two-group study of 240 participants. A computer generates a random sequence. A central system reveals each assignment only after enrolment. Participants receive either programme A or a matched comparison programme. Participants and outcome assessors are blinded to allocation, while the staff delivering the programme are not. The primary analysis follows randomised assignment.
The design contains several distinct facts: random sequence generation, central allocation concealment, participant blinding, assessor blinding, lack of provider blinding and an intention-to-treat-style primary analysis. A target phrase such as “a fully blinded random trial” would be too broad because delivery staff know the assignment.
A faithful translation preserves each role. It can still read smoothly: “Assignments were generated randomly and concealed through a central system until enrolment. Participants and outcome assessors were blinded; delivery staff were not. The primary analysis compared participants according to their original randomised groups.”
The example demonstrates the general method: translate the process as a sequence of safeguards rather than compressing all safeguards into one adjective. The result is clearer for specialists and more understandable for general readers.
24. A worked repair: allocation concealment confused with blinding
Suppose a source says: “The allocation sequence was concealed using a central randomisation service. Because the intervention was a visible training programme, participants and trainers were not blinded. Outcome assessors were blinded.”
A flawed translation might say: “The trial was not blinded because the allocation list could not be hidden.” That reverses the facts. The list was concealed before allocation; participant blinding was impossible after allocation because the intervention was visible.
The repair is to separate stages: “Upcoming allocations were concealed through a central service. Participants and trainers knew which programme was delivered, but outcome assessors remained blinded.” The target now preserves both the successful safeguard and the unavoidable limitation.
This is why allocation concealment and blinding should have distinct glossary entries. Their everyday meanings may overlap around secrecy, but their trial-design timing and purpose differ.
25. A worked repair: random assignment confused with random sampling
A fictional trial recruits volunteers from four clinics and randomly assigns them to two study groups. The source makes no claim that the volunteers are a random sample of all patients in the region.
A mistranslation says: “Patients were randomly selected from the regional population and placed into two groups.” The target has invented a population-sampling mechanism and may imply stronger representativeness than the source supports.
The repaired version says: “Volunteers recruited from four clinics were randomly assigned to two study groups.” This keeps recruitment and assignment separate. If the source later discusses external validity or generalisability, that discussion can proceed from the actual recruitment mechanism.
26. A worked repair: placebo confused with no treatment
A fictional study compares a tablet containing the active ingredient with a visually matched tablet lacking that ingredient. The source calls the comparison a placebo control.
If the target says “participants in the control group received no treatment,” it changes the participant experience and blinding context. They did receive a study intervention, though not the active ingredient under investigation.
A clearer translation is “participants in the comparison group received a matched placebo tablet.” For general readers, a brief explanation can follow: “a tablet designed to resemble the active treatment but without the active ingredient.”
Do not extend this simplified description to every placebo design. Some placebos mimic procedures, devices or schedules rather than tablets. Translate the comparator actually used.
27. Practice clinic with explained answers
Practice one. “Participants were randomly assigned” means enrolled participants were allocated using a random process. It does not by itself mean participants were randomly sampled from the population.
Practice two. “Allocation was concealed” refers to preventing foreknowledge of upcoming assignments before allocation. It is not the same as participant blinding after treatment assignment.
Practice three. A study uses a placebo but recruiters can see the upcoming randomisation list. Placebo control does not repair failed allocation concealment. Preserve both features separately.
Practice four. Participants know their intervention, but outcome assessors do not. Do not call the entire trial unblinded without explanation. State which role is blinded and which is not.
Practice five. The trial randomises schools rather than students. Translate it as cluster randomisation at the school level. Do not imply individual random assignment.
Practice six. A primary analysis follows participants according to original randomised assignment. This is an intention-to-treat principle, not a statement about whether participants intended to comply.
Practice seven. A per-protocol analysis excludes participants who do not meet prespecified adherence criteria. Preserve the analysis label and criteria. Do not rename the retained participants “valid participants.”
Practice eight. A trial says “double-blind” but does not identify the two blinded parties. Do not invent them. Preserve the source term and, where useful, the limitation that the report does not specify the roles.
Practice nine. A post hoc analysis is performed after the data are examined. Do not translate post hoc merely as “extra,” because the timing relative to data review matters.
Practice ten. A participant stops taking the intervention but remains in follow-up. “Discontinued intervention” is not the same as “withdrew from the study.” Keep trial-flow events distinct.
28. Frequently asked trial-translation questions
Is allocation concealment the same as blinding? No. Concealment protects the assignment process before allocation; blinding concerns knowledge of the assigned intervention after allocation.
Does “randomised” mean participants were randomly selected? No. It usually refers to assignment to study groups unless the source separately describes random sampling.
Does placebo-controlled mean double-blind? Not automatically. A placebo can support blinding, but the report must say who was blinded and whether blinding was maintained.
Can I translate intention-to-treat literally? Literal everyday wording can be misleading. Use the established target technical term and explain that participants are analysed according to their randomised groups under the stated analysis rule.
What is the best final check? Place each translated design term on the trial timeline. If randomisation, concealment, blinding, comparator and analysis population still occupy the same stages and roles as in the source, the design meaning has probably survived.
29. Connect this specialist guide to the wider eduKate system
This article belongs under the established Master Art of Translation architecture. It does not create a competing broad hub. The neighbouring statistical translation articles on sample size, power, confidence intervals, risk ratios, incidence, survival analysis and p-values support interpretation of trial results after the design has been translated correctly.
The Vocabulary Learning Hub helps readers learn the fine differences among terms such as randomisation, allocation, concealment, blinding and adherence. How English Works supports the grammar of agents, passive voice, sequence and reference that trial methods depend on. A passive sentence like “participants were assigned” still needs a clear method and stage.
The final rule is straightforward: preserve the design timeline. Do not let a synonym move a safeguard to another stage, do not let a familiar word invent a method that was never used, and do not let concise prose erase who knew what and when. In trial translation, causal meaning depends on procedural relationships. Those relationships must survive the language change.